

## **MENDUS AB (PUBL) HAS RESOLVED TO TRANSFER OWN SHARES**

**The board of directors of Mendus AB (publ) ("Mendus") has resolved, pursuant to the authorization from the Annual General Meeting on May 8, 2026, to transfer own shares on Nasdaq Stockholm.**

The Annual General Meeting 2026 resolved to authorize the board of directors, at one or more occasions during the period until the Annual General Meeting 2027, to transfer own shares on Nasdaq Stockholm. The purpose of the authorization is to give Mendus the possibility to preserve cash in respect of payments to employees and board members who have elected to receive their bonus and remuneration, respectively, in cash, hedge payments of taxes and other costs related to such bonus and remuneration, as well as provide the board of directors with increased flexibility to broaden Mendus ownership base through the disposal of own shares.

Based on the authorization from the Annual General Meeting 2026, the board of directors has decided to transfer up to 1,000,000 own shares on Nasdaq Stockholm. The shares can be transferred during the period 1 June 2026 – 30 April 2027 at a price per share within the registered price interval at any given time. No sales will take place during 30 days prior to the publication of a financial report. The transfer of shares will be reported via Nasdaq Stockholm in accordance with applicable rules.

At the time of this press release, there are 62,584,578 shares in Mendus, all of which are ordinary shares, whereof Mendus holds 1,054,186 shares.

**For more information, please contact:**

Erik Manting

Chief Executive Officer

E-mail: [ir@mendus.com](mailto:ir@mendus.com)

**About Mendus AB (publ)**

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies that combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU. ST. <https://www.mendus.com/>